Investigation of the Colistin Resistance among Acinetobacter Baumannii from Patients at Cairo University Hospitals, AMANI A. EL-KHOLY, AML MOHAMMED SAYED, MAY Sh. SOLIMAN, NASHWA M. REDA and AHMED S. ATTIA
Abstract
Background: Acinetobacter baumannii has been known as a problematic microorganism in healthcare settings. The treatment of infections caused by Multidrug-Resistant A. Baumannii (MDR-AB) is challenging. Colistin is an old drug that is now used as the last resort therapeutic option for treating MDR-AB however; resistance to colistin has recently been reported.
Methods: A cross sectional study was conducted in Cairo University Hospitals from January 2014 to July 2016 on 130 A. baumannii isolates from respiratory, blood, wound and urine specimens. The isolates were then tested for their susceptibility to colistin by E-test and other classes of antibi-otics by disc diffusion method. A. baumannii were exposed to the human serum to evaluate the ability of A. baumannii to resist human serum and whether this ability was affected by the acquisition of colistin resistance or not.
Results: The majority of A. baumannii isolates were XDR (92%) and few were MDR (5%). The colistin resistant A. baumannii (CoR) constituting only 4% of all isolates. There was no statistically significant difference in survival of CoR A. baumannii after exposure to the stress of human serum.
Conclusion: The colistin-resistant A. baumannii is still rare but is concerning and should be continuously evaluated as colistin is the last available therapeutic option for MDR-AB.